Loading...

ChemoCentryx

Nasdaq:CCXI
Snowflake Description

High growth potential with excellent balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CCXI
Nasdaq
$673M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The last earnings update was 18 days ago. More info.


Add to Portfolio Compare Print
  • ChemoCentryx has significant price volatility in the past 3 months.
CCXI Share Price and Events
7 Day Returns
-6.7%
NasdaqGS:CCXI
1%
US Biotechs
0.2%
US Market
1 Year Returns
-9.3%
NasdaqGS:CCXI
-4.6%
US Biotechs
2.9%
US Market
CCXI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
ChemoCentryx (CCXI) -6.7% -8.7% 3.2% -9.3% 123.1% 115.6%
US Biotechs 1% -0% -3.2% -4.6% 3.8% 9.7%
US Market 0.2% -1.6% 2.4% 2.9% 36.1% 41%
1 Year Return vs Industry and Market
  • CCXI underperformed the Biotechs industry which returned -4.6% over the past year.
  • CCXI underperformed the Market in United States of America which returned 2.9% over the past year.
Price Volatility
CCXI
Industry
5yr Volatility vs Market

CCXI Value

 Is ChemoCentryx undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of ChemoCentryx to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for ChemoCentryx.

NasdaqGS:CCXI Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 10.4%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGS:CCXI
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.38
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.383 (1 + (1- 21%) (3.15%))
1.28
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.28
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (1.28 * 5.96%)
10.36%

Discounted Cash Flow Calculation for NasdaqGS:CCXI using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for ChemoCentryx is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGS:CCXI DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 10.36%)
2019 -61.95 Analyst x4 -56.14
2020 -82.11 Analyst x3 -67.42
2021 -78.86 Analyst x4 -58.67
2022 -77.36 Analyst x3 -52.16
2023 28.31 Analyst x2 17.29
2024 38.44 Est @ 35.78% 21.28
2025 48.38 Est @ 25.87% 24.27
2026 57.54 Est @ 18.93% 26.15
2027 65.63 Est @ 14.07% 27.03
2028 72.63 Est @ 10.67% 27.11
Present value of next 10 years cash flows $-91.26
NasdaqGS:CCXI DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $72.63 × (1 + 2.73%) ÷ (10.36% – 2.73%)
$978.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $978.11 ÷ (1 + 10.36%)10
$365.05
NasdaqGS:CCXI Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-91.26 + $365.05
$273.79
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $273.79 / 58.05
$4.72
NasdaqGS:CCXI Discount to Share Price
Calculation Result
Value per share (USD) From above. $4.72
Current discount Discount to share price of $11.60
= -1 x ($11.60 - $4.72) / $4.72
-145.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of ChemoCentryx is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for ChemoCentryx's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are ChemoCentryx's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGS:CCXI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.80
NasdaqGS:CCXI Share Price ** NasdaqGS (2019-05-23) in USD $11.6
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.23x
United States of America Market PE Ratio Median Figure of 3,085 Publicly-Listed Companies 17.79x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of ChemoCentryx.

NasdaqGS:CCXI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:CCXI Share Price ÷ EPS (both in USD)

= 11.6 ÷ -0.80

-14.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChemoCentryx is loss making, we can't compare its value to the US Biotechs industry average.
  • ChemoCentryx is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does ChemoCentryx's expected growth come at a high price?
Raw Data
NasdaqGS:CCXI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -14.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
25.3%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.26x
United States of America Market PEG Ratio Median Figure of 2,123 Publicly-Listed Companies 1.54x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for ChemoCentryx, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on ChemoCentryx's assets?
Raw Data
NasdaqGS:CCXI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $1.40
NasdaqGS:CCXI Share Price * NasdaqGS (2019-05-23) in USD $11.6
United States of America Biotechs Industry PB Ratio Median Figure of 414 Publicly-Listed Biotechs Companies 3.35x
United States of America Market PB Ratio Median Figure of 5,201 Publicly-Listed Companies 1.84x
NasdaqGS:CCXI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:CCXI Share Price ÷ Book Value per Share (both in USD)

= 11.6 ÷ 1.40

8.3x

* Primary Listing of ChemoCentryx.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • ChemoCentryx is overvalued based on assets compared to the US Biotechs industry average.
X
Value checks
We assess ChemoCentryx's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. ChemoCentryx has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CCXI Future Performance

 How is ChemoCentryx expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
25.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is ChemoCentryx expected to grow at an attractive rate?
  • ChemoCentryx's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • ChemoCentryx's earnings growth is expected to exceed the United States of America market average.
  • ChemoCentryx's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGS:CCXI Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGS:CCXI Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 25.3%
NasdaqGS:CCXI Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 34.9%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGS:CCXI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGS:CCXI Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 169 -97 42 3
2022-12-31 86 -117 -39 3
2021-12-31 48 -56 -79 4
2020-12-31 50 -72 -69 7
2019-12-31 38 -65 -53 7
NasdaqGS:CCXI Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 42 -43 -40
2018-12-31 43 16 -38
2018-09-30 90 38 12
2018-06-30 90 42 17
2018-03-31 84 20 14
2017-12-31 82 5 18
2017-09-30 31 -10 -29
2017-06-30 26 -5 -30
2017-03-31 20 76 -31
2016-12-31 12 39 -40
2016-09-30 7 39 -44
2016-06-30 3 38 -48

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • ChemoCentryx's earnings are expected to grow significantly at over 20% yearly.
  • ChemoCentryx's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGS:CCXI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from ChemoCentryx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CCXI Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.50 0.51 0.48 2.00
2022-12-31 -0.53 -0.49 -0.56 2.00
2021-12-31 -1.11 -0.63 -1.46 3.00
2020-12-31 -1.12 -0.56 -1.50 7.00
2019-12-31 -0.95 -0.70 -1.28 7.00
NasdaqGS:CCXI Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.80
2018-12-31 -0.76
2018-09-30 0.25
2018-06-30 0.34
2018-03-31 0.30
2017-12-31 0.37
2017-09-30 -0.61
2017-06-30 -0.62
2017-03-31 -0.65
2016-12-31 -0.86
2016-09-30 -0.96
2016-06-30 -1.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if ChemoCentryx will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess ChemoCentryx's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
ChemoCentryx has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CCXI Past Performance

  How has ChemoCentryx performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare ChemoCentryx's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • ChemoCentryx does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare ChemoCentryx's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare ChemoCentryx's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
ChemoCentryx's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from ChemoCentryx Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGS:CCXI Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 41.66 -40.50 21.25
2018-12-31 42.88 -37.97 20.41
2018-09-30 89.84 12.47 18.91
2018-06-30 89.90 16.80 17.16
2018-03-31 83.81 14.44 16.60
2017-12-31 82.50 17.86 16.51
2017-09-30 31.09 -29.46 15.94
2017-06-30 26.31 -29.97 15.51
2017-03-31 20.17 -30.72 15.20
2016-12-31 11.94 -39.96 14.71
2016-09-30 7.05 -43.87 14.58
2016-06-30 2.80 -48.45 15.20
2016-03-31 -50.54 14.90
2015-12-31 -47.31 14.51
2015-09-30 -47.92 14.25
2015-06-30 -47.22 13.94
2015-03-31 -47.40 13.75
2014-12-31 -46.93 13.58
2014-09-30 0.73 -44.28 13.39
2014-06-30 2.25 -42.77 12.77
2014-03-31 4.13 -40.02 12.19
2013-12-31 6.06 -38.67 11.63
2013-09-30 7.48 -38.93 11.48
2013-06-30 7.09 -39.61 11.22
2013-03-31 6.33 -41.00 10.88
2012-12-31 5.42 -39.89 10.48
2012-09-30 29.33 -11.86 9.55
2012-06-30 29.64 -10.40 8.70

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if ChemoCentryx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if ChemoCentryx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if ChemoCentryx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess ChemoCentryx's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
ChemoCentryx has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CCXI Health

 How is ChemoCentryx's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up ChemoCentryx's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • ChemoCentryx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • ChemoCentryx's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of ChemoCentryx's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 10.7x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from ChemoCentryx Company Filings, last reported 1 month ago.

NasdaqGS:CCXI Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 80.64 21.20 222.11
2018-12-31 14.74 19.69 176.98
2018-09-30 21.47 14.73 173.12
2018-06-30 28.90 14.70 182.04
2018-03-31 25.53 4.70 146.57
2017-12-31 79.27 4.68 127.29
2017-09-30 37.30 0.00 120.56
2017-06-30 40.92 0.00 121.65
2017-03-31 46.32 0.00 118.45
2016-12-31 49.89 0.00 117.76
2016-09-30 54.35 0.00 121.60
2016-06-30 59.53 0.00 125.71
2016-03-31 59.83 0.00 64.19
2015-12-31 72.51 0.00 71.28
2015-09-30 81.50 0.00 73.39
2015-06-30 90.91 0.00 70.45
2015-03-31 99.41 0.00 74.84
2014-12-31 108.61 0.00 73.36
2014-09-30 118.51 0.05 85.30
2014-06-30 127.43 0.11 99.91
2014-03-31 137.19 0.18 132.57
2013-12-31 145.31 0.33 133.31
2013-09-30 153.18 1.25 124.54
2013-06-30 160.55 1.64 129.77
2013-03-31 103.29 1.65 75.91
2012-12-31 110.35 1.60 102.69
2012-09-30 118.01 1.04 125.47
2012-06-30 126.41 1.18 131.58
  • ChemoCentryx's level of debt (26.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.1% vs 26.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • ChemoCentryx has sufficient cash runway for more than 3 years based on current free cash flow.
  • ChemoCentryx has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 16.3% each year.
X
Financial health checks
We assess ChemoCentryx's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. ChemoCentryx has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CCXI Dividends

 What is ChemoCentryx's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from ChemoCentryx dividends.
If you bought $2,000 of ChemoCentryx shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate ChemoCentryx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate ChemoCentryx's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGS:CCXI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2005 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGS:CCXI Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as ChemoCentryx has not reported any payouts.
  • Unable to verify if ChemoCentryx's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of ChemoCentryx's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as ChemoCentryx has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess ChemoCentryx's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can ChemoCentryx afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. ChemoCentryx has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CCXI Management

 What is the CEO of ChemoCentryx's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Thomas Schall
COMPENSATION $3,862,225
AGE 59
TENURE AS CEO 22.3 years
CEO Bio

Dr. Thomas J. Schall, Ph.D. Founded ChemoCentryx Inc. in November 1996 and has been its Chief Executive Officer and President since 1997. Dr. Schall focuses on the discovery and development of chemokine-based therapeutics widely regarded as a Leader in chemokine research, his laboratories have been responsible for the discovery or co-discovery of almost one-third of all known chemokine receptors. From December 1993 to November 1996, he worked at the DNAX ResearchInstitute, a division of Schering-Plough Corporation, a pharmaceuticalcompany. Prior to DNAX, Dr. Schall served for seven years as a Scientist of Genentech Inc. With more than 16 years of industry experience, he has published approximately 100 articles in noted peer-reviewed journals, including Cell, Nature, Science and the Journal of Immunology. Dr. Schall has been the Chairman of the Board of ChemoCentryx, Inc. since April 2012. He has been a Director of ChemoCentryx Inc. since November 1996. He received his B.S. in biology from Northern IllinoisUniversity. Dr. Schall received his Ph.D. in Cancer Biology from Stanford University.

CEO Compensation
  • Thomas's compensation has increased whilst company is loss making.
  • Thomas's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the ChemoCentryx management team in years:

3
Average Tenure
56
Average Age
  • The tenure for the ChemoCentryx management team is about average.
Management Team

Thomas Schall

TITLE
Founder
COMPENSATION
$4M
AGE
59
TENURE
22.3 yrs

Susan Kanaya

TITLE
Executive VP
COMPENSATION
$2M
AGE
55
TENURE
2.6 yrs

Rajinder Singh

TITLE
Senior Vice President of Research
COMPENSATION
$901K
AGE
51
TENURE
3 yrs

Markus Cappel

TITLE
Senior VP
COMPENSATION
$1M
AGE
57
TENURE
14.8 yrs

Cass Kelleher

TITLE
Senior Vice President of Clinical Development
TENURE
0.1 yrs
Board of Directors Tenure

Average tenure and age of the ChemoCentryx board of directors in years:

7
Average Tenure
62
Average Age
  • The tenure for the ChemoCentryx board of directors is about average.
Board of Directors

Thomas Schall

TITLE
Founder
COMPENSATION
$4M
AGE
59
TENURE
7.1 yrs

Joe Feczko

TITLE
Director
COMPENSATION
$288K
AGE
69
TENURE
7.1 yrs

Jim Tyree

TITLE
Director
COMPENSATION
$303K
AGE
65
TENURE
6.9 yrs

Hank McKinnell

TITLE
Director
COMPENSATION
$288K
AGE
75
TENURE
2.6 yrs

Henry Showell

TITLE
Member of Scientific Advisory Board

Richard Ransohoff

TITLE
Member of Scientific Advisory Board

Craig Gerard

TITLE
Member of Scientific Advisory Board

Edward Mocarski

TITLE
Member of Scientific Advisory Board

Geoff Parker

TITLE
Director
COMPENSATION
$268K
AGE
53
TENURE
9.4 yrs

Thomas Edwards

TITLE
Director
COMPENSATION
$294K
AGE
59
TENURE
3.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
02. Nov 18 Buy Vifor Pharma AG Company 23. Oct 18 23. Oct 18 7,343,492 $11.69 $85,845,421
18. Oct 18 Sell GlaxoSmithKline plc Company 16. Oct 18 16. Oct 18 -7,343,492 $11.69 $-85,845,421
X
Management checks
We assess ChemoCentryx's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. ChemoCentryx has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CCXI News

Simply Wall St News

A Closer Look At ChemoCentryx Inc's (NASDAQ:CCXI) Impressive ROE

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows ChemoCentryx has a return on equity of 58% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Why You Need To Look At This Factor Before Buying ChemoCentryx Inc (NASDAQ:CCXI)

The other type of risk, which cannot be diversified away, is market risk. … Every stock in the market is exposed to this risk, which arises from macroeconomic factors such as economic growth and geo-political tussles just to name a few. … A widely-used metric to measure a stock's market risk is beta, and the broad market index represents a beta value of one.

Simply Wall St -

With An ROE Of 56.55%, Has ChemoCentryx Inc's (NASDAQ:CCXI) Management Done Well?

But what is more interesting is whether CCXI can sustain this above-average ratio. … If CCXI borrows debt to invest in its business, its profits will be higher. … But ROE does not capture any debt, so we only see high profits and low equity, which is great on the surface

Simply Wall St -

Should You Sell ChemoCentryx Inc (NASDAQ:CCXI) At This PE Ratio?

and want to begin learning the link between ChemoCentryx Inc (NASDAQ:CCXI)’s fundamentals and stock market performance. … Although some investors may jump to the conclusion that you should avoid the stock or sell if you own it, understanding the assumptions behind the P/E ratio might change your mind. … I will deconstruct the P/E ratio and highlight what you need to be careful of when using the P/E ratio

Simply Wall St -

Does ChemoCentryx Inc's (NASDAQ:CCXI) CEO Salary Compare Well With Others?

Given earnings are moving the right way, CEO pay should represent Schall's value creation for shareholders. … NasdaqGS:CCXI Past Future Earnings Jun 5th 18 Is CCXI's CEO overpaid relative to the market? … Taking into account the size of CCXI in terms of market cap, as well as its performance, using earnings as a proxy, it seems that Schall is compensated similar to other comparable US CEOs of profitable small-caps.

Simply Wall St -

Is ChemoCentryx Inc's (NASDAQ:CCXI) 56.55% ROE Strong Compared To Its Industry?

Check out our latest analysis for ChemoCentryx Peeling the layers of ROE – trisecting a company’s profitability Return on Equity (ROE) is a measure of ChemoCentryx’s profit relative to its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of ChemoCentryx’s equity capital deployed. … This is called the Dupont Formula: Dupont Formula ROE = profit margin × asset turnover × financial leverage ROE = (annual net profit ÷ sales) × (sales ÷ assets) × (assets ÷ shareholders’ equity) ROE = annual net profit ÷ shareholders’ equity NasdaqGS:CCXI Last Perf May 18th 18 Basically, profit margin measures how much of revenue trickles down into earnings which illustrates how efficient the business is with its cost management.

Simply Wall St -

Should You Be Tempted To Sell ChemoCentryx Inc (NASDAQ:CCXI) Because Of Its PE Ratio?

See our latest analysis for ChemoCentryx Breaking down the Price-Earnings ratio NasdaqGS:CCXI PE PEG Gauge Mar 23rd 18 P/E is often used for relative valuation since earnings power is a chief driver of investment value. … Formula Price-Earnings Ratio = Price per share ÷ Earnings per share P/E Calculation for CCXI Price per share = $14.55 Earnings per share = $0.369 ∴ Price-Earnings Ratio = $14.55 ÷ $0.369 = 39.4x On its own, the P/E ratio doesn’t tell you much; however, it becomes extremely useful when you compare it with other similar companies. … For example, if you are inadvertently comparing riskier firms with CCXI, then CCXI’s P/E would naturally be higher than its peers since investors would reward its lower risk with a higher price.

Simply Wall St -

What’s Ahead For ChemoCentryx Inc (NASDAQ:CCXI)?

The growth in development of new drugs for unmet needs, as well as the ongoing and increasing need for biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. … NasdaqGS:CCXI PE PEG Gauge Jan 12th 18 The biotech industry is trading at a PE ratio of 29x, higher than the rest of the US stock market PE of 20x. … This means the industry, on average, is relatively overvalued compared to the wider market.

Simply Wall St -

Why ChemoCentryx Inc (NASDAQ:CCXI) Has Zero-Debt On Its Balance Sheet

However, the trade-off is CCXI will have to adhere to stricter debt covenants and have less financial flexibility. … There are well-known benefits of including debt in capital structure, primarily a lower cost of capital. … CCXI’s absence of debt on its balance sheet may be due to lack of access to cheaper capital, or it may simply believe low cost is not worth sacrificing financial flexibility.

Simply Wall St -

Was ChemoCentryx Inc's (NASDAQ:CCXI) Earnings Growth Better Than Industry?

View our latest analysis for ChemoCentryx How CCXI fared against its long-term earnings performance and its industry I prefer to use data from the most recent 12 months, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … Inspecting growth from a sector-level, the US biotechnology industry has been growing its average earnings by double-digit 11.07% over the past year, and 20.18% over the previous five years. … This means that, despite the fact that ChemoCentryx is presently loss-making, it may have benefited from industry tailwinds, moving earnings into a more favorable position.What does this mean?

Simply Wall St -

CCXI Company Info

Description

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. The company is also developing Avacopan for the treatment of patients with complement 3 glomerulopathy and hidradenitis suppurativa. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis. Further, it has early stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases, and in cancer. The company was founded in 1997 and is headquartered in Mountain View, California.

Details
Name: ChemoCentryx, Inc.
CCXI
Exchange: NasdaqGS
Founded: 1997
$673,356,347
58,047,961
Website: http://www.chemocentryx.com
Address: ChemoCentryx, Inc.
850 Maude Avenue,
Mountain View,
California, 94043,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS CCXI Common Stock Nasdaq Global Select US USD 08. Feb 2012
DB 2CX Common Stock Deutsche Boerse AG DE EUR 08. Feb 2012
Number of employees
Current staff
Staff numbers
76
ChemoCentryx employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/24 00:17
End of day share price update: 2019/05/23 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.